25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GlaxoSmithKline Pharmaceuticals Limited
Buy, Hold or Sell?

Let's analyze GlaxoSmithKline Pharmaceuticals Limited together

I guess you are interested in GlaxoSmithKline Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GlaxoSmithKline Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about GlaxoSmithKline Pharmaceuticals Limited

I send you an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited.

Quick analysis of GlaxoSmithKline Pharmaceuticals Limited (30 sec.)










What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR1.52
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR104.93
Expected worth in 1 year
INR113.52
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR136.46
Return On Investment
5.1%

For what price can you sell your share?

Current Price per Share
INR2,687.60
Expected price per share
INR2,239 - INR2,759
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)

INR2,687.60

Intrinsic Value Per Share

INR241.43 - INR530.95

Total Value Per Share

INR346.36 - INR635.88

2. Growth of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




Is GlaxoSmithKline Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$211.5m$207.2m$4.3m2.0%

How much money is GlaxoSmithKline Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$70.2m$72.6m-$2.4m-3.5%
Net Profit Margin17.1%18.8%--

How much money comes from the company's main activities?

3. Financial Health of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  


Richest
#16 / 30

Most Revenue
#12 / 30

Most Profit
#10 / 30
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited? (5 min.)

Welcome investor! GlaxoSmithKline Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of GlaxoSmithKline Pharmaceuticals Limited.

What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited?

First you should know what it really means to hold a share of GlaxoSmithKline Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of GlaxoSmithKline Pharmaceuticals Limited is INR2,688. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of GlaxoSmithKline Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in GlaxoSmithKline Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR104.93. Based on the TTM, the Book Value Change Per Share is INR2.15 per quarter. Based on the YOY, the Book Value Change Per Share is INR-54.41 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR31.97 per quarter.
Based on historical numbers we can estimate the returns while holding a share of GlaxoSmithKline Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.410.0%0.410.0%0.430.0%0.470.0%0.350.0%
Usd Book Value Change Per Share0.030.0%0.030.0%-0.650.0%-0.050.0%0.160.0%
Usd Dividend Per Share0.380.0%0.380.0%1.070.0%0.500.0%0.400.0%
Usd Total Gains Per Share0.410.0%0.410.0%0.420.0%0.450.0%0.560.0%
Usd Price Per Share22.58-22.58-15.69-19.54-24.13-
Price to Earnings Ratio54.48-54.48-36.59-95.55-88.05-
Price-to-Total Gains Ratio55.62-55.62-37.00-316.64-225.98-
Price to Book Ratio18.08-18.08-12.83-15.14-14.57-
Price-to-Total Gains Ratio55.62-55.62-37.00-316.64-225.98-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share31.98244
Number of shares31
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.380.50
Usd Book Value Change Per Share0.03-0.05
Usd Total Gains Per Share0.410.45
Gains per Quarter (31 shares)12.5914.06
Gains per Year (31 shares)50.3456.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
14734063-646
294690125-13102
314210140188-19158
418913190250-25214
523616240313-32270
628319290375-38326
733022340438-44382
837725390500-50438
942529440563-57494
1047232490625-63550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.00.00.0100.0%8.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%5.03.00.062.5%5.03.00.062.5%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.00.00.0100.0%8.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.00.00.0100.0%8.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of GlaxoSmithKline Pharmaceuticals Limited

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, manufactures, and distributes pharmaceutical products and vaccines worldwide. It offers prescription and non-prescription drugs for asthma, infectious diseases, mental health, digestive conditions, and other diseases; and vaccines for various therapeutic areas, primarily cancer. The company also provides medicinal substances, such as antibiotics, endocrine products, and basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, and its salts and esters; glycosides and vegetable alkaloids; and chemically pure sugar. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2024-07-15 01:42:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is overpriced.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of GlaxoSmithKline Pharmaceuticals Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†GlaxoSmithKline Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare¬†GlaxoSmithKline Pharmaceuticals Limited to the¬†Pharmaceuticals industry mean.
  • A Net Profit Margin of 17.1%¬†means that¬†₹0.17 for each ₹1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 17.1%. The company is making a huge profit. +2
  • The TTM is 17.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ17.1%TTM17.1%0.0%
TTM17.1%YOY18.8%-1.6%
TTM17.1%5Y20.6%-3.4%
5Y20.6%10Y17.1%+3.5%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ17.1%9.8%+7.3%
TTM17.1%10.5%+6.6%
YOY18.8%10.6%+8.2%
5Y20.6%12.9%+7.7%
10Y17.1%11.6%+5.5%
1.1.2. Return on Assets

Shows how efficient GlaxoSmithKline Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†GlaxoSmithKline Pharmaceuticals Limited to the¬†Pharmaceuticals industry mean.
  • 16.6% Return on Assets means that¬†GlaxoSmithKline Pharmaceuticals Limited generated¬†₹0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 16.6%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 16.6%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ16.6%TTM16.6%0.0%
TTM16.6%YOY18.4%-1.8%
TTM16.6%5Y17.2%-0.6%
5Y17.2%10Y14.4%+2.8%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ16.6%3.8%+12.8%
TTM16.6%4.4%+12.2%
YOY18.4%5.2%+13.2%
5Y17.2%4.7%+12.5%
10Y14.4%4.8%+9.6%
1.1.3. Return on Equity

Shows how efficient GlaxoSmithKline Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†GlaxoSmithKline Pharmaceuticals Limited to the¬†Pharmaceuticals industry mean.
  • 33.2% Return on Equity means GlaxoSmithKline Pharmaceuticals Limited generated ₹0.33¬†for each¬†₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 33.2%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 33.2%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ33.2%TTM33.2%0.0%
TTM33.2%YOY35.1%-1.9%
TTM33.2%5Y32.2%+0.9%
5Y32.2%10Y25.9%+6.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ33.2%6.2%+27.0%
TTM33.2%7.0%+26.2%
YOY35.1%7.3%+27.8%
5Y32.2%6.8%+25.4%
10Y25.9%9.3%+16.6%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of GlaxoSmithKline Pharmaceuticals Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient GlaxoSmithKline Pharmaceuticals Limited is operating .

  • Measures how much profit GlaxoSmithKline Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†GlaxoSmithKline Pharmaceuticals Limited to the¬†Pharmaceuticals industry mean.
  • An Operating Margin of 0.0%¬†means the company generated ₹0.00 ¬†for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y2.4%-2.4%
5Y2.4%10Y8.2%-5.7%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.8%-17.8%
TTM-3.8%-3.8%
YOY-12.1%-12.1%
5Y2.4%8.5%-6.1%
10Y8.2%11.5%-3.3%
1.2.2. Operating Ratio

Measures how efficient GlaxoSmithKline Pharmaceuticals Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Pharmaceuticals industry mean).
  • An Operation Ratio of 1.17 means that the operating costs are ₹1.17 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.169. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.169. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.169TTM1.1690.000
TTM1.169YOY1.202-0.033
TTM1.1695Y1.249-0.080
5Y1.24910Y1.192+0.057
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1691.225-0.056
TTM1.1691.218-0.049
YOY1.2021.314-0.112
5Y1.2491.248+0.001
10Y1.1921.239-0.047
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of GlaxoSmithKline Pharmaceuticals Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Pharmaceuticals industry mean).
  • A Current Ratio of 1.84¬†means the company has ₹1.84 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.835. The company is able to pay all its short-term debts. +1
  • The TTM is 1.835. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.835TTM1.8350.000
TTM1.835YOY1.881-0.045
TTM1.8355Y1.852-0.016
5Y1.85210Y2.009-0.158
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8352.234-0.399
TTM1.8352.234-0.399
YOY1.8812.051-0.170
5Y1.8522.199-0.347
10Y2.0091.995+0.014
1.3.2. Quick Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†GlaxoSmithKline Pharmaceuticals Limited to the¬†Pharmaceuticals industry mean.
  • A Quick Ratio of 1.32¬†means the company can pay off ₹1.32 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.321. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.321. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.321TTM1.3210.000
TTM1.321YOY2.613-1.292
TTM1.3215Y2.165-0.844
5Y2.16510Y2.124+0.041
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3211.051+0.270
TTM1.3211.255+0.066
YOY2.6131.515+1.098
5Y2.1651.551+0.614
10Y2.1241.377+0.747
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of GlaxoSmithKline Pharmaceuticals Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of GlaxoSmithKline Pharmaceuticals Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†GlaxoSmithKline Pharmaceuticals Limited to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.50¬†means that GlaxoSmithKline Pharmaceuticals Limited assets are¬†financed with 50.0% credit (debt) and the remaining percentage (100% - 50.0%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.500. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.500. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.500TTM0.5000.000
TTM0.500YOY0.477+0.024
TTM0.5005Y0.469+0.031
5Y0.46910Y0.433+0.036
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5000.340+0.160
TTM0.5000.336+0.164
YOY0.4770.333+0.144
5Y0.4690.316+0.153
10Y0.4330.340+0.093
1.4.2. Debt to Equity Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†GlaxoSmithKline Pharmaceuticals Limited to the¬†Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 100.1% means that company has ₹1.00 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.001. The company is able to pay all its debts with equity. +1
  • The TTM is 1.001. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.001TTM1.0010.000
TTM1.001YOY0.910+0.090
TTM1.0015Y0.896+0.105
5Y0.89610Y0.791+0.105
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0010.547+0.454
TTM1.0010.547+0.454
YOY0.9100.499+0.411
5Y0.8960.475+0.421
10Y0.7910.557+0.234
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of GlaxoSmithKline Pharmaceuticals Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every ₹1 in earnings GlaxoSmithKline Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced but¬†always compare¬†GlaxoSmithKline Pharmaceuticals Limited to the¬†Pharmaceuticals industry mean.
  • A PE ratio of 54.48 means the investor is paying ₹54.48¬†for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 77.174. Based on the earnings, the company is expensive. -2
  • The MRQ is 54.483. Based on the earnings, the company is expensive. -2
  • The TTM is 54.483. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD77.174MRQ54.483+22.690
MRQ54.483TTM54.4830.000
TTM54.483YOY36.587+17.897
TTM54.4835Y95.553-41.070
5Y95.55310Y88.047+7.507
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD77.17423.348+53.826
MRQ54.48322.687+31.796
TTM54.48322.687+31.796
YOY36.58722.346+14.241
5Y95.55327.770+67.783
10Y88.04729.240+58.807
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 82.662. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 58.358. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 58.358. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD82.662MRQ58.358+24.304
MRQ58.358TTM58.3580.000
TTM58.358YOY50.758+7.600
TTM58.3585Y56.099+2.259
5Y56.09910Y49.663+6.436
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD82.66233.779+48.883
MRQ58.35827.332+31.026
TTM58.35827.332+31.026
YOY50.75826.360+24.398
5Y56.09931.731+24.368
10Y49.66331.253+18.410
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of GlaxoSmithKline Pharmaceuticals Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Pharmaceuticals industry mean).
  • A PB ratio of 18.08 means the investor is paying ₹18.08¬†for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 25.612. Based on the equity, the company is expensive. -2
  • The MRQ is 18.082. Based on the equity, the company is expensive. -2
  • The TTM is 18.082. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD25.612MRQ18.082+7.530
MRQ18.082TTM18.0820.000
TTM18.082YOY12.831+5.251
TTM18.0825Y15.136+2.946
5Y15.13610Y14.569+0.567
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD25.6123.877+21.735
MRQ18.0823.087+14.995
TTM18.0823.087+14.995
YOY12.8312.717+10.114
5Y15.1363.201+11.935
10Y14.5694.091+10.478
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GlaxoSmithKline Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.1472.1470%-54.407+2634%-4.276+299%13.117-84%
Book Value Per Share--104.934104.9340%102.787+2%111.929-6%102.874+2%
Current Ratio--1.8351.8350%1.881-2%1.852-1%2.009-9%
Debt To Asset Ratio--0.5000.5000%0.477+5%0.469+7%0.433+16%
Debt To Equity Ratio--1.0011.0010%0.910+10%0.896+12%0.791+26%
Dividend Per Share--31.96931.9690%90.050-64%42.385-25%33.678-5%
Eps--34.82534.8250%36.049-3%39.511-12%29.381+19%
Free Cash Flow Per Share--32.51332.5130%25.984+25%31.113+4%20.251+61%
Free Cash Flow To Equity Per Share--32.51332.5130%-65.118+300%-6.563+120%-11.973+137%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--530.947--------
Intrinsic Value_10Y_min--241.429--------
Intrinsic Value_1Y_max--38.832--------
Intrinsic Value_1Y_min--29.670--------
Intrinsic Value_3Y_max--127.628--------
Intrinsic Value_3Y_min--84.930--------
Intrinsic Value_5Y_max--229.630--------
Intrinsic Value_5Y_min--135.146--------
Market Cap--321431008911.600321431008911.6000%223429612967.000+44%278107106014.360+16%281047431749.856+14%
Net Profit Margin--0.1710.1710%0.188-9%0.206-17%0.171+0%
Operating Margin----0%-0%0.024-100%0.082-100%
Operating Ratio--1.1691.1690%1.202-3%1.249-6%1.192-2%
Pb Ratio25.612+29%18.08218.0820%12.831+41%15.136+19%14.569+24%
Pe Ratio77.174+29%54.48354.4830%36.587+49%95.553-43%88.047-38%
Price Per Share2687.600+29%1897.4001897.4000%1318.900+44%1641.660+16%2028.022-6%
Price To Free Cash Flow Ratio82.662+29%58.35858.3580%50.758+15%56.099+4%49.663+18%
Price To Total Gains Ratio78.779+29%55.61755.6170%37.003+50%316.643-82%225.976-75%
Quick Ratio--1.3211.3210%2.613-49%2.165-39%2.124-38%
Return On Assets--0.1660.1660%0.184-10%0.172-4%0.144+15%
Return On Equity--0.3320.3320%0.351-5%0.322+3%0.259+28%
Total Gains Per Share--34.11634.1160%35.643-4%38.109-10%46.795-27%
Usd Book Value--211539124.300211539124.3000%207211487.000+2%225641452.540-6%236254603.200-10%
Usd Book Value Change Per Share--0.0260.0260%-0.647+2634%-0.051+299%0.156-84%
Usd Book Value Per Share--1.2491.2490%1.223+2%1.332-6%1.224+2%
Usd Dividend Per Share--0.3800.3800%1.072-64%0.504-25%0.401-5%
Usd Eps--0.4140.4140%0.429-3%0.470-12%0.350+19%
Usd Free Cash Flow--65544486.00065544486.0000%52382610.000+25%62722339.120+4%35052741.811+87%
Usd Free Cash Flow Per Share--0.3870.3870%0.309+25%0.370+4%0.241+61%
Usd Free Cash Flow To Equity Per Share--0.3870.3870%-0.775+300%-0.078+120%-0.142+137%
Usd Market Cap--3825029006.0483825029006.0480%2658812394.307+44%3309474561.571+16%3344464437.823+14%
Usd Price Per Share31.982+29%22.57922.5790%15.695+44%19.536+16%24.133-6%
Usd Profit--70205359.00070205359.0000%72671729.200-3%79651912.200-12%64204326.511+9%
Usd Revenue--409570725.200409570725.2000%386955037.000+6%383691828.520+7%369999716.022+11%
Usd Total Gains Per Share--0.4060.4060%0.424-4%0.453-10%0.557-27%
 EOD+2 -4MRQTTM+0 -0YOY+16 -185Y+14 -2110Y+19 -16

3.2. Fundamental Score

Let's check the fundamental score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1577.174
Price to Book Ratio (EOD)Between0-125.612
Net Profit Margin (MRQ)Greater than00.171
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.321
Current Ratio (MRQ)Greater than11.835
Debt to Asset Ratio (MRQ)Less than10.500
Debt to Equity Ratio (MRQ)Less than11.001
Return on Equity (MRQ)Greater than0.150.332
Return on Assets (MRQ)Greater than0.050.166
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.045
Ma 20Greater thanMa 502,593.285
Ma 50Greater thanMa 1002,488.774
Ma 100Greater thanMa 2002,238.400
OpenGreater thanClose2,640.000
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in INR. All numbers in thousands.

Summary
Total Assets35,566,175
Total Liabilities17,789,778
Total Stockholder Equity17,776,397
 As reported
Total Liabilities 17,789,778
Total Stockholder Equity+ 17,776,397
Total Assets = 35,566,175

Assets

Total Assets35,566,175
Total Current Assets27,984,186
Long-term Assets7,581,989
Total Current Assets
Cash And Cash Equivalents 641,712
Short-term Investments 17,926,520
Net Receivables 2,220,571
Inventory 5,250,482
Other Current Assets 20,298
Total Current Assets  (as reported)27,984,186
Total Current Assets  (calculated)26,059,583
+/- 1,924,603
Long-term Assets
Property Plant Equipment 3,107,318
Intangible Assets 235,538
Long-term Assets Other 6,060
Long-term Assets  (as reported)7,581,989
Long-term Assets  (calculated)3,348,916
+/- 4,233,073

Liabilities & Shareholders' Equity

Total Current Liabilities15,249,461
Long-term Liabilities2,540,317
Total Stockholder Equity17,776,397
Total Current Liabilities
Accounts payable 6,254,097
Other Current Liabilities 17,727
Total Current Liabilities  (as reported)15,249,461
Total Current Liabilities  (calculated)6,271,824
+/- 8,977,637
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt186,650
Long-term Liabilities  (as reported)2,540,317
Long-term Liabilities  (calculated)186,650
+/- 2,353,667
Total Stockholder Equity
Retained Earnings 8,551,862
Total Stockholder Equity (as reported)17,776,397
Total Stockholder Equity (calculated)8,551,862
+/- 9,224,535
Other
Capital Stock1,694,060
Common Stock Shares Outstanding 169,406
Net Invested Capital 17,776,397
Net Working Capital 12,734,725
Property Plant and Equipment Gross 5,938,615



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
> Total Assets 
30,548,849
30,038,353
39,474,827
39,113,109
31,355,410
31,146,474
46,332,778
33,265,848
35,566,175
35,566,17533,265,84846,332,77831,146,47431,355,41039,113,10939,474,82730,038,35330,548,849
   > Total Current Assets 
21,737,270
16,742,459
21,864,082
20,094,620
17,748,814
22,026,398
37,080,323
24,942,645
27,984,186
27,984,18624,942,64537,080,32322,026,39817,748,81420,094,62021,864,08216,742,45921,737,270
       Cash And Cash Equivalents 
562,336
1,068,622
1,100,100
300,300
60,000
2,061,192
561,271
349,009
641,712
641,712349,009561,2712,061,19260,000300,3001,100,1001,068,622562,336
       Short-term Investments 
0
7,672,460
10,690,145
10,490,145
9,570,145
7,320,000
25,446,923
16,191,788
17,926,520
17,926,52016,191,78825,446,9237,320,0009,570,14510,490,14510,690,1457,672,4600
       Net Receivables 
1,265,650
1,707,967
1,469,589
1,204,873
998,012
2,156,046
2,052,389
1,923,750
2,220,571
2,220,5711,923,7502,052,3892,156,046998,0121,204,8731,469,5891,707,9671,265,650
       Inventory 
5,258,666
4,257,974
5,001,833
4,864,935
4,830,322
5,466,981
5,346,954
4,599,704
5,250,482
5,250,4824,599,7045,346,9545,466,9814,830,3224,864,9355,001,8334,257,9745,258,666
       Other Current Assets 
882,363
894,389
1,639,395
352,065
276,371
2,066,161
233,666
232,855
20,298
20,298232,855233,6662,066,161276,371352,0651,639,395894,389882,363
   > Long-term Assets 
0
13,312,189
17,660,119
19,051,760
13,606,596
9,107,000
9,252,247
8,323,200
7,581,989
7,581,9898,323,2009,252,2479,107,00013,606,59619,051,76017,660,11913,312,1890
       Property Plant Equipment 
4,717,116
8,259,263
11,730,238
13,670,968
8,270,867
3,541,241
3,254,472
3,151,200
3,107,318
3,107,3183,151,2003,254,4723,541,2418,270,86713,670,96811,730,2388,259,2634,717,116
       Intangible Assets 
0
322,473
726,818
655,400
496,251
433,640
344,974
340,908
235,538
235,538340,908344,974433,640496,251655,400726,818322,4730
       Long-term Assets Other 
0
306,098
408,414
322,761
149,203
501,700
13,318
524,300
6,060
6,060524,30013,318501,700149,203322,761408,414306,0980
> Total Liabilities 
8,716,369
9,969,795
18,901,538
17,714,817
13,149,361
16,363,875
19,703,220
15,853,118
17,789,778
17,789,77815,853,11819,703,22016,363,87513,149,36117,714,81718,901,5389,969,7958,716,369
   > Total Current Liabilities 
5,792,107
7,202,325
15,998,637
14,543,195
10,242,572
13,545,807
16,984,288
13,263,701
15,249,461
15,249,46113,263,70116,984,28813,545,80710,242,57214,543,19515,998,6377,202,3255,792,107
       Short-term Debt 
0
0
0
0
0
240
0
0
0
00024000000
       Short Long Term Debt 
0
6,060
4,060
4,060
1,530
240
0
0
0
0002401,5304,0604,0606,0600
       Accounts payable 
0
5,224,802
6,462,468
4,825,341
3,575,851
4,644,700
5,705,487
4,277,900
6,254,097
6,254,0974,277,9005,705,4874,644,7003,575,8514,825,3416,462,4685,224,8020
       Other Current Liabilities 
0
312,952
199,157
150,647
651,258
2,638,500
1,292
562,000
17,727
17,727562,0001,2922,638,500651,258150,647199,157312,9520
   > Long-term Liabilities 
0
2,767,470
2,902,901
3,171,622
2,906,789
2,818,100
2,718,932
2,589,400
2,540,317
2,540,3172,589,4002,718,9322,818,1002,906,7893,171,6222,902,9012,767,4700
       Long term Debt Total 
15,950
9,890
5,830
1,770
268,612
202,499
76,235
34,554
0
034,55476,235202,499268,6121,7705,8309,89015,950
> Total Stockholder Equity
21,832,480
20,068,558
20,573,289
21,398,292
18,206,049
14,782,599
26,629,558
17,412,730
17,776,397
17,776,39717,412,73026,629,55814,782,59918,206,04921,398,29220,573,28920,068,55821,832,480
   Common Stock
847,030
847,030
847,030
1,694,060
1,694,060
1,694,060
1,694,060
1,694,060
0
01,694,0601,694,0601,694,0601,694,0601,694,060847,030847,030847,030
   Retained Earnings 
20,985,450
19,221,528
19,726,259
19,704,232
16,511,989
13,088,539
24,935,498
15,718,670
8,551,862
8,551,86215,718,67024,935,49813,088,53916,511,98919,704,23219,726,25919,221,52820,985,450
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 000000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue34,417,708
Cost of Revenue-14,198,485
Gross Profit20,219,22320,219,223
 
Operating Income (+$)
Gross Profit20,219,223
Operating Expense-26,032,852
Operating Income8,384,856-5,813,629
 
Operating Expense (+$)
Research Development0
Selling General Administrative2,284,033
Selling And Marketing Expenses0
Operating Expense26,032,8522,284,033
 
Net Interest Income (+$)
Interest Income678,503
Interest Expense-17,987
Other Finance Cost-0
Net Interest Income660,516
 
Pretax Income (+$)
Operating Income8,384,856
Net Interest Income660,516
Other Non-Operating Income Expenses0
Income Before Tax (EBT)8,161,8798,384,856
EBIT - interestExpense = -17,987
5,899,610
5,917,597
Interest Expense17,987
Earnings Before Interest and Taxes (EBIT)08,179,866
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax8,161,879
Tax Provision-2,262,269
Net Income From Continuing Ops5,899,6105,899,610
Net Income5,899,610
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-660,516
 

Technical Analysis of GlaxoSmithKline Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of GlaxoSmithKline Pharmaceuticals Limited. The general trend of GlaxoSmithKline Pharmaceuticals Limited is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine GlaxoSmithKline Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GlaxoSmithKline Pharmaceuticals Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 2,700 < 2,759.

The bearish price targets are: 2,510 > 2,503 > 2,239.

Tweet this
GlaxoSmithKline Pharmaceuticals Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging¬†trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GlaxoSmithKline Pharmaceuticals Limited. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GlaxoSmithKline Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a¬†lagging momentum¬†indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GlaxoSmithKline Pharmaceuticals Limited. The current macd is 30.34.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GlaxoSmithKline Pharmaceuticals Limited price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for GlaxoSmithKline Pharmaceuticals Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the GlaxoSmithKline Pharmaceuticals Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GlaxoSmithKline Pharmaceuticals Limited. The current adx is 19.27.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy GlaxoSmithKline Pharmaceuticals Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows¬†the current trend.
  • Shows¬†potential entry signals.
  • Shows¬†¬†potential exit signals.
  • Can be used to place¬†trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GlaxoSmithKline Pharmaceuticals Limited. The current sar is 2,517.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum¬†indicator, meaning the signals are instant.
  • Ranges¬†between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GlaxoSmithKline Pharmaceuticals Limited. The current rsi is 62.05. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading¬†momentum¬†indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges¬†between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GlaxoSmithKline Pharmaceuticals Limited. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the GlaxoSmithKline Pharmaceuticals Limited price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Stochastic Oscillator ChartGlaxoSmithKline Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,¬†the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GlaxoSmithKline Pharmaceuticals Limited. The current cci is 187.83.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GlaxoSmithKline Pharmaceuticals Limited. The current cmo is 32.31.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and¬†-100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GlaxoSmithKline Pharmaceuticals Limited. The current willr is -42.64455123.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that GlaxoSmithKline Pharmaceuticals Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GlaxoSmithKline Pharmaceuticals Limited Daily Williams %R ChartGlaxoSmithKline Pharmaceuticals Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold¬†

Score

Let's take a look at the Bollinger Bands of GlaxoSmithKline Pharmaceuticals Limited.

GlaxoSmithKline Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GlaxoSmithKline Pharmaceuticals Limited. The current atr is 102.90.

GlaxoSmithKline Pharmaceuticals Limited Daily Average True Range (ATR) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GlaxoSmithKline Pharmaceuticals Limited. The current obv is 272,137.

GlaxoSmithKline Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartGlaxoSmithKline Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GlaxoSmithKline Pharmaceuticals Limited. The current mfi is 66.31.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
GlaxoSmithKline Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GlaxoSmithKline Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-05-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-23ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

GlaxoSmithKline Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.045
Ma 20Greater thanMa 502,593.285
Ma 50Greater thanMa 1002,488.774
Ma 100Greater thanMa 2002,238.400
OpenGreater thanClose2,640.000
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of GlaxoSmithKline Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on GlaxoSmithKline Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GlaxoSmithKline Pharmaceuticals Limited

I send you an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about GlaxoSmithKline Pharmaceuticals Limited.

Receive notifications about GlaxoSmithKline Pharmaceuticals Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.